浙江中西医结合杂志
浙江中西醫結閤雜誌
절강중서의결합잡지
ZHEJIANG JOURNAL OF INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE
2015年
1期
12-13,107
,共3页
管彩虹%赵凯%楼雅芳%朱黎红%吴清
管綵虹%趙凱%樓雅芳%硃黎紅%吳清
관채홍%조개%루아방%주려홍%오청
肺癌细胞%趋化因子CCL22%肿瘤侵袭%肿瘤转移
肺癌細胞%趨化因子CCL22%腫瘤侵襲%腫瘤轉移
폐암세포%추화인자CCL22%종류침습%종류전이
lung cancer cells%chemokine CCL22%tumor invasion%tumor migration
目的：观察趋化因子CCL22对肺癌SBC-5细胞迁移和侵袭能力的影响。方法取肺癌细胞系SBC-5细胞，RPMI-1640培养基培养，5%CO2培养箱孵育，清洗消化后传代培养。予100ng/mL的CCL22诱导肺癌SBC-5细胞，设Control组、CCL22组（100ng/mL）、MIX组（CCL22100ng/mL+蛋白激酶抑制剂U012610μmol），观察细胞迁移及侵袭能力的变化；加入蛋白激酶抑制剂（U0126）后细胞迁移及侵袭能力的变化。结果 CCL22诱导肺癌SBC-5细胞后，CCL22组细胞迁移距离（351.9±16.4）μm，明显大于Control组的（112.6±27.2）μm和MIX组的（145.1±29.6）μm（P<0.05）， MIX组和Control组比较差异无统计学意义（P>0.05）。CCL22组平均侵袭细胞数（505.5±66.3）个，显著高于Control组的（199.2±32.8）个和MIX组的（95.7±19.1）个（P<0.05），MIX组明显低于Control组（P<0.05）。结论趋化因子CCL22可在体外诱导肺癌SBC-5细胞迁移和侵袭，而蛋白激酶抑制剂（U0126）可抑制CCL22诱导肺癌细胞的迁移及侵袭。
目的：觀察趨化因子CCL22對肺癌SBC-5細胞遷移和侵襲能力的影響。方法取肺癌細胞繫SBC-5細胞，RPMI-1640培養基培養，5%CO2培養箱孵育，清洗消化後傳代培養。予100ng/mL的CCL22誘導肺癌SBC-5細胞，設Control組、CCL22組（100ng/mL）、MIX組（CCL22100ng/mL+蛋白激酶抑製劑U012610μmol），觀察細胞遷移及侵襲能力的變化；加入蛋白激酶抑製劑（U0126）後細胞遷移及侵襲能力的變化。結果 CCL22誘導肺癌SBC-5細胞後，CCL22組細胞遷移距離（351.9±16.4）μm，明顯大于Control組的（112.6±27.2）μm和MIX組的（145.1±29.6）μm（P<0.05）， MIX組和Control組比較差異無統計學意義（P>0.05）。CCL22組平均侵襲細胞數（505.5±66.3）箇，顯著高于Control組的（199.2±32.8）箇和MIX組的（95.7±19.1）箇（P<0.05），MIX組明顯低于Control組（P<0.05）。結論趨化因子CCL22可在體外誘導肺癌SBC-5細胞遷移和侵襲，而蛋白激酶抑製劑（U0126）可抑製CCL22誘導肺癌細胞的遷移及侵襲。
목적：관찰추화인자CCL22대폐암SBC-5세포천이화침습능력적영향。방법취폐암세포계SBC-5세포，RPMI-1640배양기배양，5%CO2배양상부육，청세소화후전대배양。여100ng/mL적CCL22유도폐암SBC-5세포，설Control조、CCL22조（100ng/mL）、MIX조（CCL22100ng/mL+단백격매억제제U012610μmol），관찰세포천이급침습능력적변화；가입단백격매억제제（U0126）후세포천이급침습능력적변화。결과 CCL22유도폐암SBC-5세포후，CCL22조세포천이거리（351.9±16.4）μm，명현대우Control조적（112.6±27.2）μm화MIX조적（145.1±29.6）μm（P<0.05）， MIX조화Control조비교차이무통계학의의（P>0.05）。CCL22조평균침습세포수（505.5±66.3）개，현저고우Control조적（199.2±32.8）개화MIX조적（95.7±19.1）개（P<0.05），MIX조명현저우Control조（P<0.05）。결론추화인자CCL22가재체외유도폐암SBC-5세포천이화침습，이단백격매억제제（U0126）가억제CCL22유도폐암세포적천이급침습。
Objective To investigate the effect of chemokine CCL22 on migration and invasion of lung cancer cell line SBC-5. Methods Lung cancer cell line SBC-5 cells were cultured with RPMI-1640 medium and incu-bated in an incubator with 5% CO2, then the cell was washed and digested to subculture. The SBC-5 cells sub-cultured were divided into control group, CCL22 group(100ng/mL), and MIX group(CCL22 100ng/mL+protease in-hibitor U0126 10μmol). The cells were treated with the corresponding drugs in each group. Capability of lung cancer cell migration and invasion was observed after treatment in each group. Results After induction with CCL22, the migration distance of SBC-5 cells was increased(351.9±16.4μm) compared with that in control(112.6± 27.2μm) and MIX group (145.1±29.6μm, all P<0.05); no significant difference in the migration distance was noted between control and MIX groups(P>0.05). Cell invasion in CCL22 group(505.5±66.3) was seen more than that in control (199.2±32.8) and MIX groups (95.7±19.1, all P<0.05), and a significant difference was found between the latter two groups (P<0.05). Conclusion Chemokine CCL22 can induce migration and invasion of lung cancer cell line SBC-5 in vitro, while protease inhibitor (U0126) may inhibit the migration and invasion of lung cancer cells induced by CCL22.
